(Q38025157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Clinical management of the hypereosinophilic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Florence Roufosse

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Hematology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

275-89; quiz 290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22780208%20AND%20SRC:MED&resulttype=core&format=json

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

7 February 2020

cites work

1 reference

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report

21 January 2018

1 reference

Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Refining the definition of hypereosinophilic syndrome

21 January 2018

1 reference

World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

21 January 2018

1 reference

21 January 2018

Eosinophilic disorders

1 reference

Practical approach to the patient with hypereosinophilia

21 January 2018

1 reference

Hypereosinophilic syndrome: current approach to diagnosis and treatment.

21 January 2018

1 reference

Lymphocytic variant hypereosinophilic syndromes

21 January 2018

1 reference

Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome

21 January 2018

1 reference

Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.

21 January 2018

1 reference

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

21 January 2018

1 reference

Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon

21 January 2018

1 reference

The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).

21 January 2018

1 reference

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

21 January 2018

1 reference

Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics

21 January 2018

1 reference

More than 13 years of hypereosinophila associated with clonal CD3-CD4+ lymphocytosis of TH2/TH0 type

21 January 2018

1 reference

Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.

21 January 2018

1 reference

Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation

21 January 2018

1 reference

IFN-alpha 2b reduces IL-2 production and IL-2 receptor function in primary CD4+ T cells

21 January 2018

1 reference

Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells

21 January 2018

1 reference

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

Treatment of hypereosinophilic syndrome with imatinib mesilate

21 January 2018

1 reference

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

21 January 2018

1 reference

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

21 January 2018

1 reference

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

21 January 2018

1 reference

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

21 January 2018

1 reference

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia

21 January 2018

1 reference

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome

21 January 2018

1 reference

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

21 January 2018

1 reference

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.

21 January 2018

1 reference

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome

21 January 2018

1 reference

Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis

21 January 2018

1 reference

'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.

21 January 2018

1 reference

Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.

21 January 2018

1 reference

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

21 January 2018

1 reference

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

21 January 2018

1 reference

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

21 January 2018

1 reference

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.

21 January 2018

1 reference

Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib

21 January 2018

1 reference

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib

21 January 2018

1 reference

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

21 January 2018

1 reference

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

21 January 2018

1 reference

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

21 January 2018

1 reference

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 January 2018

1 reference

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

21 January 2018

1 reference

Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody

21 January 2018

1 reference

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

21 January 2018

1 reference

The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma

21 January 2018

1 reference

Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides

21 January 2018

1 reference

NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations

21 January 2018

1 reference

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.

21 January 2018

1 reference

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome

21 January 2018

1 reference

Extramedullary molecular evidence of the 5′KIAA1509/3′PDGFRB fusion gene in chronic eosinophilic leukemia

21 January 2018

1 reference